The stock of DoorDash, which rose 6% on Friday, recorded a 1.3% gain this week, bringing its year-to-date gain to 23%. On November 13, DoorDash announced a partnership with Old Navy, a division of GAP ...

Major stock indexes finished mixed Friday, with the Dow Jones Industrial Average declining for a second straight session but ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...

Key Takeaways Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.The $221.50 per share offer is more than twice Cidara's ...

Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.

Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...

Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara's stock (CDTX) soaring 106% in recent morning trading, enough to make it the biggest gainer on the major U.S. exchanges. The ...

“We don’t suffer from FOMO [fear of missing out],” says the portfolio manager and senior wealth adviser with Propellus Wealth ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

FREE TO READ] Bidding war goes down to wire for company whose lead drug is potential alternative to vaccines for vulnerable patients ...

Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday’s closing price, for a total ...